Group items tagged

Future prospects and key markets trends of the make-up, skin care and beauty product markets in the world indicate a prospective future for the global skin care and beauty product market. Key market insights unveiling the market trends and prospects for make-up, skin care and beauty product markets in the world generate opportunities for marketers and attract swarming competition. Key products segments include lip make-up products, eye make-up products, pedicure and manicure products, make-up and skin care powders, other make-up, skin care and beauty products.

Emerging players with potentially strong product portfolio is expected to capture the global Xerosis treatment market. It is essential for the marketers to design effective counter-strategies to gain competitive advantage. A promising pipeline indicates mergers and acquisitions. Devising corrective measures for pipeline projects would also require an in-depth understanding of the Xerosis pipeline depth and focus of indication therapeutics.

An extensive analysis of the cosmetic and toiletry product markets in the world displays a strong growth pattern. Segmentation of cosmetic and toiletry product by type segregates the fast growing products and displays a prospective future. Key product segments include soap, dental and oral hygiene products, hair products, make-up, skin care and beauty products, toilet waters and perfumes, shaving products, antiperspirants and deodorants, bath products, room deodorizing and perfuming products.

The non-existence of effective vaccine against HCV leads the healthcare market in United States to be driven by therapeutics. Vertexs Incivek was amongst the first DAA HCV therapies launched in the US and is the current market leader. Inciveks improved efficacy over the previous standard of care in the treatment of the most prevalent HCV genotype in the US, HCV GT1, which enabled the drug to quickly capture the market. Adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.